Given that UPS and DDLPS patients with low CD3+ TIL levels are considered to have “immune cold” tumours and unlikely to benefit from anti-PD-1/PD-L1 inhibitors, we mined the proteomic data to establish if other biological pathways that could be exploited for therapy were present. Here, PDCD1 is linked to neoplasm.